ArticleACS chemical biology2013
On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7.
Article in ACS chemical biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 69 citations in OpenAlex.
- Checkpoint-Directed Glycoengineering Reprograms the Vascular Lumen for Siglec-Mediated Immune Regulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- One-Step Glycoengineering of NK Cells With High-Affinity Siglec Ligands for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- New Sialic Acid-Binding Site of SIGLEC-7.Advances in experimental medicine and biology · 2026Review
- Understanding the Glycosylation Pathways Involved in the Biosynthesis of the Sulfated Glycan Ligands for Siglecs.ACS chemical biology · 2025Article
- Comprehensive Modular Synthesis of Ganglioside Glycans and Evaluation of their Binding Affinities to Siglec-7 and Siglec-9.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Combatting melioidosis with chemical synthetic lethality.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Reshaping the tumor microenvironment by degrading glycoimmune checkpoints Siglec-7 and -9.bioRxiv : the preprint server for biology · 2024Article
- Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.Cancers · 2024Review
- Dissecting the Ability of Siglecs To Antagonize Fcγ Receptors.ACS central science · 2024Article
- Discovery of 7-Azanorbornane-Based Dual Agonists for the Delta and Kappa Opioid Receptors through an In Situ Screening Protocol.Molecules (Basel, Switzerland) · 2023Article
- Glycomimetics for the inhibition and modulation of lectins.Chemical Society reviews · 2023Review
- Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.Cancer biology & medicine · 2023Review
- Sugar-decorated carbon dots: a novel tool for targeting immunomodulatory receptors.Nanoscale advances · 2022Article
- Directing CAR NK Cells via the Metabolic Incorporation of CAR Ligands into Malignant Cell Glycans.ACS chemical biology · 2022Article
- Modulation of Siglec-7 Signaling Via In Situ-Created High-AffinityACS central science · 2021Article
- Siglec Ligands.Cells · 2021Review
- Probing the binding specificities of human Siglecs by cell-based glycan arrays.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.Angewandte Chemie (International ed. in English) · 2021Article
- Modulation of immune cell reactivity withProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Terminal Epitope-Dependent Branch Preference of Siglecs TowardFrontiers in molecular biosciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The Siglec family of sialic acid-binding proteins are differentially expressed on white blood cells of the immune system and represent an attractive class of targets for cell-directed therapy. Nanoparticles decorated with high-affinity Siglec ligands show promise for delivering cargo to Siglec-bearing cells, but this approach has been limited by a lack of ligands with suitable affinity and selectivity. Building on previous work employing solution-phase sialoside library synthesis and subsequent microarray screening, we herein report a more streamlined 'on-chip' synthetic approach. By printing a small library of alkyne sialosides and subjecting these to 'on-chip' click reactions, the largest sialoside analogue library to date was generated. Siglec-screening identified a selective Siglec-7 ligand, which when displayed on liposomal nanoparticles, allows for targeting of Siglec-7(+) cells in peripheral human blood. In silico docking to the crystal structure of Siglec-7 provides a rationale for the affinity gains observed for this novel sialic acid analogue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.